Management of pain in Parkinson's disease

CNS Drugs

Volumn 26, Issue 11, 2012, Pages 937-948

  Sophie, Munazza ^a   Ford, Blair ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; DOPAMINE; LEVODOPA;

ALTERNATIVE MEDICINE; ANALGESIA; ARTICLE; BACKACHE; CONSULTATION; DYSTONIA; HUMAN; KINESIOTHERAPY; KNEE PAIN; MOTOR PERFORMANCE; MUSCULOSKELETAL PAIN; NEUROIMAGING; NEUROPATHIC PAIN; NEUROTRANSMISSION; NOCICEPTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANGE OF MOTION; SHOULDER PAIN; STEREOTAXIC SURGERY; TOTAL KNEE REPLACEMENT;

ANALGESICS; COMPLEMENTARY THERAPIES; DOPAMINE; DOPAMINE AGENTS; EXERCISE THERAPY; HUMANS; PAIN; PAIN MANAGEMENT; PAIN PERCEPTION; PARKINSON DISEASE;

EID: 84873468508     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0005-2     Document Type: Article

References (123)

1. Huse DM, Schulman K, Orsini L, et al. Burden of illness in Parkinson's disease. Mov Disord. 2005;20(11):1449-54.
2. Politis M, Wu K, Molloy S, et al. Parkinson's disease symptoms: the patient's perspective. Mov Disord. 2010;25(11):1646-51.
3. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology. 2002;59(3):408-13.
4. Parkinson J. An essay on the shaking palsy. London: Whittingham and Rowland; 1817.
5. Gowers WR. A manual of disease of the nervous system. Philadelphia: Blakiston; 1888.
6. Charcot JM. Lectures on diseases of the nervous system. London: The New Sydenham Society; 1877.
7. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5(3):235-45.
8. Beiske AG, Loge JH, Ronningen A, et al. Pain in Parkinson's disease: prevalence and characteristics. Pain. 2009;141(1-2):173-7.
9. Santos-Garcia D, Abella-Corral J, Aneiros-Diaz A, et al. Pain in Parkinson's disease: prevalence, characteristics, associated factors, and relation with other non motor symptoms, quality of life, autonomy, and caregiver burden (in Spanish). Rev Neurol. 2011;52(7):385-93.
10. O'Sullivan SS, Williams DR, Gallagher DA, et al. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord. 2008;23(1):101-6.
11. Perrotta A, Sandrini G, Serrao M, et al. Facilitated temporal summation of pain at spinal level in Parkinson's disease. Mov Disord. 2011;26(3):442-8.
12. Dauvilliers Y. Insomnia in patients with neurodegenerative conditions. Sleep Med. 2007;8(Suppl. 4):S27-34.
13. Ehrt U, Larsen JP, Aarsland D. Pain and its relationship to depression in Parkinson disease. Am J Geriatr Psychiatry. 2009;17(4):269-75.
14. Roh JH, Kim BJ, Jang JH, et al. The relationship of pain and health-related quality of life in Korean patients with Parkinson's disease. Acta Neurol Scand. 2009;119(6):397-403.
15. Goetz CG, Tanner CM, Levy M, et al. Pain in Parkinson's disease. Mov Disord. 1986;1(1):45-9.
16. Winter Y, von Campenhausen S, Arend M, et al. Health-related quality of life and its determinants in Parkinson's disease: results of an Italian cohort study. Parkinsonism Relat Disord. 2011;17(4):265-9.
17. Rahman S, Griffin HJ, Quinn NP, et al. Quality of life in Parkinson's disease: the relative importance of the symptoms. Mov Disord. 2008;23(10):1428-34.
18. Quittenbaum BH, Grahn B. Quality of life and pain in Parkinson's disease: a controlled cross-sectional study. Parkinsonism Relat Disord. 2004;10(3):129-36.
19. Lee MA, Walker RW, Hildreth TJ, et al. A survey of pain in idiopathic Parkinson's disease. J Pain Symptom Manage. 2006;32(5):462-9.
20. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord. 2010;25(6):704-9.
21. Goy ER, Carter J, Ganzini L. Neurologic disease at the end of life: caregiver descriptions of Parkinson disease and amyotrophic lateral sclerosis. J Palliat Med. 2008;11(4):548-54.
22. Marsala S, Tinazzi M, Vitaliani R, et al. Spontaneous pain, pain threshold, and pain tolerance in Parkinson's disease. J Neurol. 2011;258(4):627-33.
23. Tinazzi M, Del Vesco C, Fincati E, et al. Pain and motor complications in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2006;77(7):822-5.
24. Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain. 1995;60(1):3-38.
25. Barnes CD, Fung SJ, Adams WL. Inhibitory effects of substantia nigra on impulse transmission from nociceptors. Pain. 1979;6(2):207-15.
26. Burkey AR, Carstens E, Jasmin L. Dopamine reuptake inhibition in the rostral agranular insular cortex produces antinociception. J Neurosci. 1999;19(10):4169-79.
27. Honey CR, Stoessl AJ, Tsui JK, et al. Unilateral pallidotomy for reduction of parkinsonian pain. J Neurosurg. 1999;91(2):198-201.
28. Loher TJ, Burgunder JM, Weber S, et al. Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 2002;73(4):395-9.
29. Scherder E, Wolters E, Polman C, et al. Pain in Parkinson's disease and multiple sclerosis: its relation to the medial and lateral pain systems. Neurosci Biobehav Rev. 2005;29(7):1047-56.
30. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211.
31. Schestatsky P, Kumru H, Valls-Sole J, et al. Neurophysiologic study of central pain in patients with Parkinson disease. Neurology. 2007;69(23):2162-9.
32. Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, et al. Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study. J Neurol Neurosurg Psychiatry. 2007;78(10):1140-2.
33. Brefel-Courbon C, Payoux P, Thalamas C, et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord. 2005;20(12):1557-63.
34. Mylius V, Engau I, Teepker M, et al. Pain sensitivity and descending inhibition of pain in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2009;80(1):24-8.
35. Slaoui T, Mas-Gerdelat A, Ory-Magne F, et al. Levodopa modifies pain thresholds in Parkinson's disease patients (in French). Rev Neurol (Paris). 2007;163(1):66-71.
36. Serrao M, Parisi L, Valente G, et al. L-Dopa decreases cutaneous nociceptive inhibition of motor activity in Parkinson's disease. Acta Neurol Scand. 2002;105(3):196-201.
37. Braak H, Sastre M, Bohl JR, et al. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol. 2007;113(4):421-9.
38. Nolano M, Provitera V, Estraneo A, et al. Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. Brain. 2008;131(Pt 7):1903-11.
39. Wood PB. Role of central dopamine in pain and analgesia. Exp Rev Neurother. 2008;8(5):781-97.
40. Juri C, Rodriguez-Oroz M, Obeso JA. The pathophysiological basis of sensory disturbances in Parkinson's disease. J Neurol Sci. 2010;289(1-2):60-5.
41. Djaldetti R, Shifrin A, Rogowski Z, et al. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology. 2004;62(12):2171-5.
42. Dellapina E, Gerdelat-Mas A, Ory-Magne F, et al. Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord. 2011;26(1):153-7.
43. Barone P. Neurotransmission in Parkinson's disease: beyond dopamine. Eur J Neurol. 2010;17(3):364-76.
44. Defazio G, Berardelli A, Fabbrini G, et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol. 2008;65(9):1191-4.
45. Negre-Pages L, Regragui W, Bouhassira D, et al. Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. Mov Disord. 2008;23(10):1361-9.
46. Letro GH, Quagliato EM, Viana MA. Pain in Parkinson's disease. Arq Neuropsiquiatr. 2009;67(3A):591-4.
47. Mott S, Kenrick M, Dixon M, et al. Pain as a sequela of Parkinson disease. Aust Fam Physician. 2004;33(8):663-4.
48. Ford B. Pain in Parkinson's disease. Clin Neurosci. 1998;5(2):63-72.
49. Hanagasi HA, Akat S, Gurvit H, et al. Pain is common in Parkinson's disease. Clin Neurol Neurosurg. 2011;113(1):11-3.
50. Duvoisin RC, Marsden CD. Note on the scoliosis of Parkinsonism. J Neurol Neurosurg Psychiatry. 1975;38(8):787-93.
51. Bissonnette B. Pseudorheumatoid deformity of the feet associated with parkinsonism. J Rheumatol. 1986;13(4):825-6.
52. Broetz D, Eichner M, Gasser T, et al. Radicular and nonradicular back pain in Parkinson's disease: a controlled study. Mov Disord. 2007;22(6):853-6.
53. Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol. 2006;25(Suppl. 1):S22-9.
54. Ford B. Pain in Parkinson's disease. Mov Disord. 2010;25(Suppl. 1):S98-103.
55. Madden MB, Hall DA. Shoulder pain in Parkinson's disease: a case-control study. Mov Disord. 2010;25(8):1105-6.
56. Yucel A, Kusbeci OY. Magnetic resonance imaging findings of shoulders in Parkinson's disease. Mov Disord. 2010;25(15):2524-30.
57. Kryzak TJ, Sperling JW, Schleck CD, et al. Total shoulder arthroplasty in patients with Parkinson's disease. J Shoulder Elbow Surg. 2009;18(1):96-9.
58. Etchepare F, Rozenberg S, Mirault T, et al. Back problems in Parkinson's disease: an underestimated problem. Joint Bone Spine. 2006;73(3):298-302.
59. Koller H, Acosta F, Zenner J, et al. Spinal surgery in patients with Parkinson's disease: experiences with the challenges posed by sagittal imbalance and the Parkinson's spine. Eur Spine J. 2010;19(10):1785-94.
60. Babat LB, McLain RF, Bingaman W, et al. Spinal surgery in patients with Parkinson's disease: construct failure and progressive deformity. Spine. 2004;29(18):2006-12.
61. Moon SH, Lee HM, Chun HJ, et al. Surgical outcome of lumbar fusion surgery in patients with Parkinson disease. J Spinal Disord Tech (Epub 2011 Jun 16).
62. Margraf NG, Wrede A, Rohr A, et al. Camptocormia in idiopathic Parkinson's disease: a focal myopathy of the paravertebral muscles. Mov Disord. 2010;25(5):542-51.
63. Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology. 2005;65(3):355-9.
64. Finsterer J, Strobl W. Presentation, etiology, diagnosis, and management of camptocormia. Eur Neurol. 2010;64(1):1-8.
65. Tolosa E, Compta Y. Dystonia in Parkinson's disease. J Neurol. 2006;253 Suppl. 7:VII7-13.
66. Jankovic J, Albanese A, Hallett M. Unique properties of botulinum toxins. Toxicon. 2009;54(5):675.
67. Sako W, Nishio M, Maruo T, et al. Subthalamic nucleus deep brain stimulation for camptocormia associated with Parkinson's disease. Mov Disord. 2009;24(7):1076-9.
68. Hellmann MA, Djaldetti R, Israel Z, et al. Effect of deep brain subthalamic stimulation on camptocormia and postural abnormalities in idiopathic Parkinson's disease. Mov Disord. 2006;21(11):2008-10.
69. Koller WC. Sensory symptoms in Parkinson's disease. Neurology. 1984;34(7):957-9.
70. Macaulay W, Geller JA, Brown AR, et al. Total knee arthroplasty and Parkinson disease: enhancing outcomes and avoiding complications. J Am Acad Orthop Surg. 2010;18(11):687-94.
71. Ashour R, Tintner R, Jankovic J. Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol. 2005;4(7):423-31.
72. Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord. 2006;21(11):1856-63.
73. Deonna T, Ferreira A. Idiopathic fluctuating dystonia: a case of foot dystonia and writer's cramp responsive to l-dopa. Dev Med Child Neurol. 1985;27(6):819-21.
74. Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon. 2009;54(5):614-23.
75. Moore TJ, Evans W, Murray D. Operative management of foot and ankle equinovarus associated with focal dystonia. Foot Ankle Int. 1998;19(4):229-31.
76. Quinn NP. Classification of fluctuations in patients with Parkinson's disease. Neurology. 1998;51(2 Suppl. 2):S25-9.
77. Kidron D, Melamed E. Forms of dystonia in patients with Parkinson's disease. Neurology. 1987;37(6):1009-11.
78. Juncos JL, Fabbrini G, Mouradian MM, et al. Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations. Arch Neurol. 1987;44(10):1010-2.
79. Lera G, Vaamonde J, Rodriguez M, et al. Cabergoline in Parkinson's disease: long-term follow-up. Neurology. 1993;43(12):2587-90.
80. Pastor P, Tolosa E. Cabergoline in the treatment of Parkinson's disease (in Spanish). Neurologia. 2003;18(4):202-9.
81. Juri C, Rodriguez-Oroz MC, Burguera JA, et al. Pain and dyskinesia in Parkinson's disease. Mov Disord. 2010;25(1):130-2.
82. Karlsborg M, Korbo L, Regeur L, et al. Duodopa pump treatment in patients with advanced Parkinson's disease. Dan Med Bull. 2010;57(6):A4155.
83. Lees AJ. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin Pharmacol. 1993;7(3-4):121-8.
84. Sanford M, Scott LJ. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease. CNS Drugs. 2011;25(8):699-719.
85. Stocchi F, Ruggieri S, Antonini A, et al. Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration. J Neural Transm Suppl. 1988;27:27-33.
86. Melamed E. Early-morning dystonia: a late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol. 1979;36(5):308-10.
87. Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol. 1988;23(1):73-8.
88. Simuni T, Lyons KE, Pahwa R, et al. Treatment of early Parkinson's disease: part 2. Eur Neurol. 2009;61(4):206-15.
89. Cordivari C, Misra VP, Catania S, et al. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord. 2001;16(5):907-13.
90. Pacchetti C, Albani G, Martignoni E, et al. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord. 1995;10(3):333-6.
91. Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 1998;339(16):1105-11.
92. Ford B, Greene P, Louis ED, et al. Use of intrathecal baclofen in the treatment of patients with dystonia. Arch Neurol. 1996;53(12):1241-6.
93. Kodama M, Kasahara T, Hyodo M, et al. Effect of low-frequency repetitive transcranial magnetic stimulation combined with physical therapy on L-dopa-induced painful off-period dystonia in Parkinson's disease. Am J Phys Med Rehabil. 2011;90(2):150-5.
94. Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord. 2007;22(10):1379-89. (quiz 523).
95. Thomas A, Iacono D, Luciano AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004;75(1):141-3.
96. Metman LV, Del Dotto P, LePoole K, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol. 1999;56(11):1383-6.
97. Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology. 2004;62(3):381-8.
98. Anderson VC, Burchiel KJ, Hogarth P, et al. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol. 2005;62(4):554-60.
99. Preston DN, Grimes JD. Radial compression neuropathy in advanced Parkinson's disease. Arch Neurol. 1985;42(7):695-6.
100. Kurlan R, Baker P, Miller C, et al. Severe compression neuropathy following sudden onset of parkinsonian immobility. Arch Neurol. 1985;42(7):720.
101. Rajabally YA, Martey J. Neuropathy in Parkinson disease: prevalence and determinants. Neurology. 2011;77(22):1947-50.
102. Toth C, Breithaupt K, Ge S, et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol. 2010;68(1):28-36.
103. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009;122(10 Suppl):S22-32.
104. Snider SR, Fahn S, Isgreen WP, et al. Primary sensory symptoms in parkinsonism. Neurology. 1976;26(5):423-9.
105. Quinn NP, Koller WC, Lang AE, et al. Painful Parkinson's disease. Lancet. 1986;1(8494):1366-9.
106. Ford B, Louis ED, Greene P, et al. Oral and genital pain syndromes in Parkinson's disease. Mov Disord. 1996;11(4):421-6.
107. Bayulkem K, Lopez G. Nonmotor fluctuations in Parkinson's disease: clinical spectrum and classification. J Neurol Sci. 2010;289(1-2):89-92.
108. Raudino F. Non motor off in Parkinson's disease. Acta Neurol Scand. 2001;104(5):312-5.
109. Witjas T, Kaphan E, Regis J, et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. Mov Disord. 2007;22(12):1729-34.
110. Maruo T, Saitoh Y, Hosomi K, et al. Deep brain stimulation of the subthalamic nucleus improves temperature sensation in patients with Parkinson's disease. Pain. 2011;152(4):860-5.
111. Gierthmuhlen J, Arning P, Binder A, et al. Influence of deep brain stimulation and levodopa on sensory signs in Parkinson's disease. Mov Disord. 2010;25(9):1195-202.
112. Goodwin VA, Richards SH, Taylor RS, et al. The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2008;23(5):631-40.
113. Reuter I, Mehnert S, Leone P, et al. Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson's disease. J Aging Res. 2011;2011:232473.
114. Pecci C, Rivas MJ, Moretti CM, et al. Use of complementary and alternative therapies in outpatients with Parkinson's disease in Argentina. Mov Disord. 2010;25(13):2094-8.
115. Kim SR, Lee TY, Kim MS, et al. Use of complementary and alternative medicine by Korean patients with Parkinson's disease. Clin Neurol Neurosurg. 2009;111(2):156-60.
116. Tan LC, Lau PN, Jamora RD, et al. Use of complementary therapies in patients with Parkinson's disease in Singapore. Mov Disord. 2006;21(1):86-9.
117. Ferry P, Johnson M, Wallis P. Use of complementary therapies and non-prescribed medication in patients with Parkinson's disease. Postgrad Med J. 2002;78(924):612-4.
118. Rajendran PR, Thompson RE, Reich SG. The use of alternative therapies by patients with Parkinson's disease. Neurology. 2001;57(5):790-4.
119. Cristian A, Katz M, Cutrone E, et al. Evaluation of acupuncture in the treatment of Parkinson's disease: a double-blind pilot study. Mov Disord. 2005;20(9):1185-8.
120. Shulman LM, Wen X, Weiner WJ, et al. Acupuncture therapy for the symptoms of Parkinson's disease. Mov Disord. 2002;17(4):799-802.
121. Kim HJ, Paek SH, Kim JY, et al. Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. J Neurol. 2008;255(12):1889-94.
122. Oshima H, Katayama Y, Morishita T, et al. Subthalamic nucleus stimulation for attenuation of pain related to Parkinson disease. J Neurosurg. 2012;116(1):99-106.
123. Silva EG, Viana MA, Quagliato EM. Pain in Parkinson's disease: analysis of 50 cases in a clinic of movement disorders. Arq Neuropsiquiatr. 2008;66(1):26-9.